Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Fineline Cube Sep 10, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company

AstraZeneca’s Oncology Executive Michael Lai to Leave Company in June

Fineline Cube Jun 17, 2025

Lai Minglong (Michael Lai), head of AstraZeneca’s (AZ, NASDAQ: AZN) global oncology business Dato-DXd and...

Company Deals

Eli Lilly Close to Acquiring Verve Therapeutics for Up to USD 1.3 Billion

Fineline Cube Jun 17, 2025

US-based pharmaceutical giant Eli Lilly & Co., (NYSE: LLY) is reportedly in advanced negotiations to...

Company Drug

Pediatrix Therapeutics Wins Macau Approval for Neffy Epinephrine Nasal Spray

Fineline Cube Jun 17, 2025

China-based Pediatrix Therapeutics announced that it has received marketing approval in Macau for its neffy...

Company Drug

Minova Pharmaceuticals Launches Rongzhi, China’s First Injectable Adipocytolytic Drug

Fineline Cube Jun 17, 2025

Nanjing-based Minova Pharmaceuticals Co., Ltd announced last week that it has received marketing approval from...

Legal / IP

RemeGen Secures 1,827-Day Patent Extension for Telitacicept in China

Fineline Cube Jun 17, 2025

China-based pharmaceutical firm RemeGen (HKG: 9995) announced that the China National Intellectual Property Administration has...

Company Drug

Fujian Cosunter Gains Ethics Approval for Phase III Study of Neracorvir in CHB Patients

Fineline Cube Jun 17, 2025

China-based Fujian Cosunter Pharmaceutical Co., Ltd. (SHE: 300436) announced that it has received ethical approval...

Company Drug

CDE Accepts NDA for Ark Bio’s Azstarys, a Priority-Reviewed ADHD Treatment

Fineline Cube Jun 17, 2025

China’s Center for Drug Evaluation (CDE) has officially accepted the New Drug Application (NDA) for...

Company Drug

Ascentage Pharma Highlights Hematology Advances at EHA 2025, Focus on Olverembatinib and APG-5918

Fineline Cube Jun 17, 2025

China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) unveiled 13 research presentations at the 2025 European...

Company Deals

Clover Biopharmaceuticals Terminates Adimmune Influenza Vaccine Pact Over Market Shifts

Fineline Cube Jun 17, 2025

China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) announced the exercise of unilateral termination rights under its...

Company Drug

Fosun Pharma’s Serplulimab Approved in Singapore and Malaysia for ES-SCLC Treatment

Fineline Cube Jun 17, 2025

Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196, SHA: 600196) announced that its subsidiary Shanghai...

Policy / Regulatory

China’s NHC Unveils 2025 Healthcare Reforms to Tackle Procurement and Service Irregularities

Fineline Cube Jun 16, 2025

China’s National Health Commission (NHC) has released the 2025 Key Tasks for Rectifying Improper Practices...

Company Deals Medical Device

Thermo Fisher Mulls $4B Diagnostic Business Sale Amid Healthcare Sector Turbulence

Fineline Cube Jun 16, 2025

US-based life sciences giant Thermo Fisher Scientific Inc. (NYSE: TMO) is reported by the Financial...

Company Drug

Changchun High-Tech Subsidiary Gains NMPA Approval for CINV Drug Trial

Fineline Cube Jun 16, 2025

China-based Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary...

Company Drug

Novo Nordisk Advances Amycretin for Weight Management in Phase III Trials

Fineline Cube Jun 16, 2025

Denmark-based pharmaceutical major Novo Nordisk (NYSE: NVO) announced plans to advance both subcutaneous and oral...

Company Drug

FDA OKs MSD’s Keytruda for Perioperative Head and Neck Cancer Treatment With PD-L1 Expression

Fineline Cube Jun 16, 2025

US pharmaceutical giant Merck, Sharp & Dohme (MSD; NYSE: MRK) announced that the US Food...

Company Drug

GSK Seeks EMA Approval to Expand RSV Vaccine Arexvy Use to Adults Aged 18+

Fineline Cube Jun 16, 2025

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) has announced that the European Medicines Agency (EMA)...

Company

UCB Announces Investment in U.S. Biologics Production Facility

Fineline Cube Jun 16, 2025

Belgium-based biopharmaceutical company UCB (EBR: UCB) announced plans to invest in a cutting-edge biologics production...

Company Deals

Gene Solutions Partners with Shenzhen USK Bio to Advance Precision Oncology in Southern China

Fineline Cube Jun 16, 2025

Vietnam-headquartered Gene Solutions announced a Memorandum of Understanding (MOU) with China’s Shenzhen USK Bioscience Co.,...

Company Deals

MRI and Astellas Alliance to Boost Japanese Drug Discovery Startups

Fineline Cube Jun 16, 2025

Japan-based Mitsubishi Research Institute, Inc. (MRI) and Astellas Pharma Inc. (TYO: 4503) announced the signing...

Company Drug

MSD Wins NMPA Approval for Keytruda-Lenvima Combo in Hepatocellular Carcinoma

Fineline Cube Jun 16, 2025

US-based Merck, Sharp & Dohme (MSD; NYSE: MRK) announced that China’s National Medical Products Administration...

Posts pagination

1 … 196 197 198 … 719

Recent updates

  • Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone
  • Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline
  • Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis
  • Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404
  • NMPA Accepts Hengrui’s New Drug Application for Ribupatide Injection – Dual GLP‑1/GIP Receptor Agonist Nears Approval for Type 2 Diabetes in China
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Company Deals

Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.